463 related articles for article (PubMed ID: 24991733)
1. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
Bonderman D; Pretsch I; Steringer-Mascherbauer R; Jansa P; Rosenkranz S; Tufaro C; Bojic A; Lam CSP; Frey R; Ochan Kilama M; Unger S; Roessig L; Lang IM
Chest; 2014 Nov; 146(5):1274-1285. PubMed ID: 24991733
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.
Mascherbauer J; Grünig E; Halank M; Hohenforst-Schmidt W; Kammerlander AA; Pretsch I; Steringer-Mascherbauer R; Ulrich S; Lang IM; Wargenau M; Frey R; Bonderman D
Wien Klin Wochenschr; 2016 Dec; 128(23-24):882-889. PubMed ID: 27590259
[TBL] [Abstract][Full Text] [Related]
3. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
Bonderman D; Ghio S; Felix SB; Ghofrani HA; Michelakis E; Mitrovic V; Oudiz RJ; Boateng F; Scalise AV; Roessig L; Semigran MJ;
Circulation; 2013 Jul; 128(5):502-11. PubMed ID: 23775260
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Mittleman RS; Profy AT; Seferovic JP; Reasner D; Konstam MA
Am Heart J; 2020 Apr; 222():183-190. PubMed ID: 32105984
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.
Galiè N; Grimminger F; Grünig E; Hoeper MM; Humbert M; Jing ZC; Keogh AM; Langleben D; Rubin LJ; Fritsch A; Davie N; Ghofrani HA
J Heart Lung Transplant; 2017 May; 36(5):509-519. PubMed ID: 28190787
[TBL] [Abstract][Full Text] [Related]
8. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
Dachs TM; Duca F; Rettl R; Binder-Rodriguez C; Dalos D; Ligios LC; Kammerlander A; Grünig E; Pretsch I; Steringer-Mascherbauer R; Ablasser K; Wargenau M; Mascherbauer J; Lang IM; Hengstenberg C; Badr-Eslam R; Kastner J; Bonderman D
Eur Heart J; 2022 Sep; 43(36):3402-3413. PubMed ID: 35909264
[TBL] [Abstract][Full Text] [Related]
9. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
[TBL] [Abstract][Full Text] [Related]
10. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
D'Armini AM; Ghofrani HA; Kim NH; Mayer E; Morsolini M; Pulido-Zamudio T; Simonneau G; Wilkins MR; Curram J; Davie N; Hoeper MM
J Heart Lung Transplant; 2015 Mar; 34(3):348-55. PubMed ID: 25813765
[TBL] [Abstract][Full Text] [Related]
11. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
12. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA
J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961
[TBL] [Abstract][Full Text] [Related]
13. Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study.
Ahmadi A; Thornhill RE; Pena E; Renaud JM; Promislow S; Chandy G; Davies RA; Stewart DJ; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Beanlands RS; deKemp RA; Mielniczuk LM
Can J Cardiol; 2018 Sep; 34(9):1137-1144. PubMed ID: 30170668
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension.
Murata M; Kawakami T; Kataoka M; Moriyama H; Hiraide T; Kimura M; Endo J; Kohno T; Itabashi Y; Fukuda K
Cardiology; 2021; 146(1):130-136. PubMed ID: 33238268
[TBL] [Abstract][Full Text] [Related]
15. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
[TBL] [Abstract][Full Text] [Related]
16. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
Grimminger F; Weimann G; Frey R; Voswinckel R; Thamm M; Bölkow D; Weissmann N; Mück W; Unger S; Wensing G; Schermuly RT; Ghofrani HA
Eur Respir J; 2009 Apr; 33(4):785-92. PubMed ID: 19129292
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Hoeper MM; Halank M; Wilkens H; Günther A; Weimann G; Gebert I; Leuchte HH; Behr J
Eur Respir J; 2013 Apr; 41(4):853-60. PubMed ID: 22936711
[TBL] [Abstract][Full Text] [Related]
18. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
20. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
Rai N; Veeroju S; Schymura Y; Janssen W; Wietelmann A; Kojonazarov B; Weissmann N; Stasch JP; Ghofrani HA; Seeger W; Schermuly RT; Novoyatleva T
Biomed Res Int; 2018; 2018():3293584. PubMed ID: 29511676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
